Stock ASMB ASSEMBLY BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Assembly Biosciences, Inc.

Equities

ASMB

US0453962070

Pharmaceuticals

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
13.4 USD +3.00% Intraday chart for Assembly Biosciences, Inc. +1.90% +36.16%
May. 08 Assembly Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 28 Assembly Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 661.6 199.8 111.5 63.41 53.96 73.47 - -
Enterprise Value (EV) 1 661.6 199.8 111.5 63.41 53.96 73.47 73.47 73.47
P/E ratio -5.5 x -3.46 x -0.78 x -0.68 x -0.74 x -1.42 x -1.4 x -1.22 x
Yield - - - - - - - -
Capitalization / Revenue 41.4 x 2.53 x 17.8 x - 7.53 x - - 1.11 x
EV / Revenue 41.4 x 2.53 x 17.8 x - 7.53 x - - 1.11 x
EV / EBITDA - - - - - - - -
EV / FCF -8,132,216 x -3,149,843 x - -749,884 x - - - -
FCF Yield -0% -0% - -0% - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 2,695 2,752 3,988 4,065 5,483 5,483 - -
Reference price 2 245.5 72.60 27.96 15.60 9.841 13.40 13.40 13.40
Announcement Date 3/4/20 2/25/21 3/11/22 3/22/23 3/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 15.96 79.1 6.254 - 7.163 - - 66.08
EBITDA - - - - - - - -
EBIT 1 -102.7 -64.78 -91.05 -94.11 -64.65 -58.61 -61.08 -70.96
Operating Margin -643.44% -81.89% -1,455.87% - -902.5% - - -107.39%
Earnings before Tax (EBT) 1 -98.41 -62.15 -132.4 -93.09 -61.2 -52.46 -54.81 -64.56
Net income 1 -97.63 -62.15 -129.9 -93.09 -61.23 -52.46 -54.81 -64.56
Net margin -611.63% -78.57% -2,076.35% - -854.78% - - -97.7%
EPS 2 -44.64 -21.00 -36.00 -23.04 -13.38 -9.460 -9.600 -10.97
Free Cash Flow -81.35 -63.43 - -84.56 - - - -
FCF margin -509.63% -80.18% - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 3/4/20 2/25/21 3/11/22 3/22/23 3/28/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - 7.163 - 5.959 6.137 6.321
EBITDA - - - - - - - - - - - - -
EBIT 1 -21.25 -23.16 -24.57 -23.4 -22.98 -19.56 -17.49 -15.05 -12.55 -10.73 -13.84 -15.86 -18.18
Operating Margin - - - - - - - - -175.22% - -232.27% -258.48% -287.6%
Earnings before Tax (EBT) 1 -62.79 -23.09 -24.46 -23.14 -22.4 -18.95 -16.9 -14.42 -10.93 -9.077 -12.34 -14.36 -16.68
Net income 1 -60.26 -23.09 -24.46 -23.14 -22.4 -18.95 -16.9 -14.42 -10.96 -9.077 -12.34 -14.36 -16.68
Net margin - - - - - - - - -153.04% - -207.1% -234.04% -263.87%
EPS 2 -16.44 -5.760 -6.120 -5.760 -5.520 -4.440 -3.840 -3.240 -1.740 -1.660 -2.230 -2.580 -2.980
Dividend per Share - - - - - - - - - - - - -
Announcement Date 3/11/22 5/12/22 8/9/22 11/8/22 3/22/23 5/4/23 8/9/23 11/8/23 3/28/24 5/8/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow -81.4 -63.4 - -84.6 - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex - 0.47 2.24 0.1 - - - -
Capex / Sales - 0.59% 35.8% - - - - -
Announcement Date 3/4/20 2/25/21 3/11/22 3/22/23 3/28/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
13.4 USD
Average target price
36 USD
Spread / Average Target
+168.66%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Specialty & Advanced Pharmaceuticals

1st Jan change Capi.
ASSEMBLY BIOSCIENCES, INC. Stock Assembly Biosciences, Inc.
+36.16% 73.47M
MERCK KGAA Stock Merck KGaA
+7.91% 72.81B
KYOWA KIRIN CO. LTD. Stock Kyowa Kirin Co. Ltd.
+12.64% 9.13B
SK BIOPHARMACEUTICALS CO., LTD. Stock SK Biopharmaceuticals Co., Ltd.
-10.56% 5.13B
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD. Stock Shenyang Xingqi Pharmaceutical Co.,Ltd.
+58.79% 4.99B
YUHAN CORPORATION Stock Yuhan Corporation
+4.07% 3.9B
BETTA PHARMACEUTICALS CO., LTD. Stock Betta Pharmaceuticals Co., Ltd.
-16.90% 2.48B
CHANGCHUN BCHT BIOTECHNOLOGY CO. Stock Changchun BCHT Biotechnology Co.
-26.13% 2.32B
SHANGHAI SHYNDEC PHARMACEUTICAL CO., LTD. Stock Shanghai Shyndec Pharmaceutical Co., Ltd.
+19.31% 2.17B
VELOXIS PHARMACEUTICALS A/S Stock Veloxis Pharmaceuticals A/S
-0.50% 1.64B
Specialty & Advanced Pharmaceuticals
  1. Stock Market
  2. Equities
  3. ASMB Stock
  4. Financials Assembly Biosciences, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW